{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:01:33Z","timestamp":1784815293034,"version":"3.55.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medcli.2026.107473","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:26:37Z","timestamp":1779899197000},"page":"107473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of thrombotic microangiopathy during tislelizumab therapy for lung cancer"],"prefix":"10.1016","volume":"166","author":[{"given":"Nannan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2026.107473_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.medcli.2026.107473_bib0035","first-page":"8599","article-title":"Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies","volume":"30","author":"Font","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.medcli.2026.107473_bib0040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjh.18577","article-title":"Drug-induced thrombotic thrombocytopenic purpura: a systematic review and review of European and North American pharmacovigilance data","volume":"201","author":"Schofield","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2026.107473_bib0045","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1111\/nep.70067","article-title":"Renal-limited thrombotic microangiopathy induced by fruquintinib and tislelizumab: a case report","volume":"30","author":"Liu","year":"2025","journal-title":"Nephrology"},{"key":"10.1016\/j.medcli.2026.107473_bib0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18651","article-title":"A \u2018needle in a haystack\u2019: drug-induced thrombotic thrombocytopenic purpura\u2014association or causality?","volume":"201","author":"Scully","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:14:17Z","timestamp":1784812457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775326001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0025775326001235"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107473","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of thrombotic microangiopathy during tislelizumab therapy for lung cancer","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107473"}}